Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aerogen Pharma Limited
With
Ohio State University
This study will evaluate the potential therapeutic benefit of VentaProst in treating patients with COVID-19 at risk for respiratory and/ or cardiac/circulatory failure. This is a double-blind, placebo controlled study of VentaProst in 10 confirmed COVID-19 patients compared to 10- COVID-19 placebo patients to assess the efficacy and safety of VentaProst given over 10 days at varying doses.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed COVID-19 positive by RT-PCR test
Patients who require invasive mechanical ventilation.
Consent or professional consent obtained
You may not be if
Patients on ECMO support.
Patients receiving another inhalation research medication or inhaled nitric oxide.
